Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer

Sun, Yan; Li, Sha; Qiao, Zhi; Shang, Zhi; Xia, Zhijun; Niu, Xiaomin; Qian, Liqiang; Zhang, Yan; Fan, Liu-Yin; Cao, Cheng-Xi; Xiao, Hua

doi:10.1016/j.aca.2017.06.005

Cited by 120 publications

(82 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was observed after liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis that 11 potential proteins were detected in both samples. This result indicates that body fluid-derived exosomes expressed similar cancer related molecules [155].…”

Section: Article Body Templatementioning

confidence: 69%

Exosomes: Fighting Cancer With Cancer

et al. 2018

View full text Add to dashboard Cite

Exosomes are nanovesicles secreted by many cells, including cancer cells. Extensive research has been carried out to validate potential applications of exosomes and to evaluate their efficiency in a wide range of diseases, including cancer. The current knowledge on the origin, biogenesis and composition of exosomes is described. This review then focusses on the use of exosomes in cancer diagnostics and therapeutics.

show abstract

Section: Article Body Templatementioning

confidence: 69%

Exosomes: Fighting Cancer With Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…They determined that a starch‐packed affinity chromatography column combined with filtration was the optimal method to deplete saliva of amylase and enrich for EV proteins. Using this methodology, they explored the proteome of EVs from NSCLC patients as well as healthy subjects using LC–MS/MS‐based label‐free quantification . In their first report, both serum and saliva were analyzed from three healthy controls and three lung cancer patients.…”

Section: Salivamentioning

confidence: 99%

Tumor‐Derived Extracellular Vesicles as a Novel Source of Protein Biomarkers for Cancer Diagnosis and Monitoring

Ruhen

Meehan

2019

Proteomics

View full text Add to dashboard Cite

“Liquid biopsies” have received attention as a complementary tool for traditional tissue biopsies that may enhance the spectrum of analysis for tumor‐derived factors. One such factor gaining prominence in the liquid biopsy field is extracellular vesicles (EVs), membrane‐bound nanovesicles which are secreted by cells into biofluids such as blood, urine, and saliva. EVs are released in both physiological and pathological conditions and can transport a variety of molecules, including proteins, metabolites, RNA, microRNAs, and DNA, to distant sites throughout the body. As such, they are emerging as a promising source of tumor biomarkers for the noninvasive diagnosis, prognosis, and monitoring of cancer patients. In particular, the wealth of tumor‐related information that can be gleaned from the EV proteomic cargo has become apparent through mass spectrometric analysis, which has provided new benchmarks for clinically focused biomarker research. In this review, the current achievements in the use of MS for identifying potential EV‐derived protein biomarkers of cancer are explored, and the techniques and challenges involved in this pursuit are summarized.

show abstract

“…Furthermore, the use of exosomes as cancer and disease biomarkers is now very common place, with serum exosomal proteomic signature being a particular focus for many studies on elucidating unique signatures. 6,7 One of the most exciting uses of serum exosomes for biomarker discovery was by Melo et al in 2015 indicating that exosomal Glipican-1 was a discriminate factor for pinpointing pancreatic cancer. 8 The current study presented focuses on describing the exosomal proteomic analysis of an asbestos exposure mouse model.…”

Section: Introductionmentioning

confidence: 99%

Mouse serum exosomal proteomic signature in response to asbestos exposure

Munson

Lam

MacPherson

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Asbestos-induced diseases like fibrosis and mesothelioma are very aggressive, without any treatment options. These diseases are diagnosed only at the terminal stages due to lack of early stage biomarkers. The recent discovery of exosomes as circulating biomarkers led us to look for exosomal biomarkers of asbestos exposure in mouse blood. In our model, mice were exposed to asbestos as a single bolus dose by oropharyngeal aspiration. Fifty-six days later blood was collected, exosomes were isolated from plasma and characterized and subjected to proteomic analysis using Tandem Mass Tag labeling. We identified many proteins, some of which were more abundant in asbestos exposed mouse serum exosomes, and three selected proteins were validated by immunoblotting. Our study is the first to show that serum exosomal proteomic signatures can reveal some important proteins relevant to asbestos exposure that have the potential to be validated as candidate biomarkers. We hope to extrapolate the positive findings of this study to humans in future studies.

show abstract

Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer

Cited by 120 publications

References 31 publications

Exosomes: Fighting Cancer With Cancer

Exosomes: Fighting Cancer With Cancer

Tumor‐Derived Extracellular Vesicles as a Novel Source of Protein Biomarkers for Cancer Diagnosis and Monitoring

Mouse serum exosomal proteomic signature in response to asbestos exposure

Contact Info

Product

Resources

About